Skip to main content
$5.03 -$0.21 (-4.0%)

04:00 PM EDT on 10/22/21

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: No stars

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Current Price $5.03 Mkt Cap $46.4M
Open $5.19 P/E Ratio 0.00
Prev. Close $5.03 Div. (Yield) $0.00 (0.0%)
Daily Range $5.01 - $5.26 Volume 38,036
52-Wk Range $3.12 - $11.42 Avg. Daily Vol. 143,563

Caps

How do you think NASDAQ:CYCC will perform against the market?

Add Stock to CAPS Watchlist

All Players

74 Outperform
9 Underperform
 

All-Star Players

8 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CYCC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

UnstableEnabled (< 20)
Submitted December 21, 2013

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.It's… More

imrhh (< 20)
Submitted May 06, 2007

This is one of Zack's #1 rated stocks. I do not understand their reasoning for this though. The chart that came up on my computer showed this stock starting at around zero and then going on a very steady decline to at least minus 100%. Call me crazy,… More

NASDAQ:CYCC VS S&P 500 (SPY)

Fools bullish on NASDAQ:CYCC are also bullish on:

Fools bearish on NASDAQ:CYCC are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CYCC.

Recs

0
Member Avatar oscillation (74.99) Submitted: 6/1/2015 1:40:33 AM : Outperform Start Price: $8.64 NASDAQ:CYCC Score: -155.69

nev

Recs

1
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $44.94 NASDAQ:CYCC Score: -237.26

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

0
Member Avatar toegar2000 (31.21) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $64.19 NASDAQ:CYCC Score: -290.78

Looks good IMO

Leaderboard

Find the members with the highest scoring picks in CYCC.

Score Leader

BravoBevo

BravoBevo (99.97) Score: +727.06

In the event of a natural disaster like a tornado, earthquake, or snow avalanche, keep cheese sticks in your pockets so the search dogs will find you first.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BravoBevo 99.97 3/10/2020 Outperform 5Y $0.50 +904.00% +62.13% +841.87 0 Comment
portefeuille2 99.00 4/29/2019 Outperform 5Y $0.68 +633.27% +54.39% +578.88 0 Comment
longtermgrowth09 38.69 8/3/2010 Underperform 5Y $137.26 -96.34% +302.88% +399.22 0 Comment
mrtofoo 21.53 1/7/2008 Underperform 5Y $425.66 -98.82% +235.46% +334.28 0 Comment
imrhh < 20 5/7/2007 Underperform 3M $637.27 -99.21% +217.53% +316.74 2 Comments
bluebare 27.81 12/7/2012 Underperform 5Y $75.63 -93.36% +219.08% +312.44 0 Comment
klaracat 31.17 10/22/2012 Underperform 5Y $60.93 -91.76% +216.56% +308.32 0 Comment
MFBurritoSquat 73.54 8/29/2012 11/28/2012 Underperform 1Y $37.47 -86.60% +220.21% +306.81 0 Comment
GenericMind5885 98.46 2/27/2015 Underperform 5Y $17.97 -72.07% +114.52% +186.60 0 Comment
Momentum21 33.97 3/1/2018 Outperform 5Y $1.52 +229.37% +67.13% +162.25 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CYCC.